News

Notice of Convocation of the 160th Annual General Meeting of Shareholders

Amendments to Articles of Incorporation

Transcript of FY2024 Financial Results

Financial Results and supplement for FY2024

Financial Results and supplement for FY2024

Shionogi, Nagasaki University, Saraya, and Connect Afya Enter into a Comprehensive Partnership Agreement to Support Antimicrobial Stewardship in Kenya

Regarding the Collaborative Research Agreement on Hearing Loss with Cilcare

Notice of Commencement of Tender Offer for Shares of TORII PHARMACEUTICAL CO., LTD. (Securities Code: 4551)

Announcement of Agreement on Company Split (Simplified Absorption-Type Split) of Japan Tobacco Inc.'s Pharmaceutical Business and Acquisition of Shares of Akros Pharma Inc. by Shionogi Inc. (Making it a Subsidiary)

Shionogi Announces Further Agreement with Apnimed for Sleep Disorder Treatments - Introduction of New Assets to Joint Venture Shionogi-Apnimed Sleep Science – (SASS)

Notice of Revisions to Dividend Forecasts (Dividend Increase)

ESCMID Global 2025: Shionogi presents real-world data demonstrating better clinical outcomes when Fetcroja® / Fetroja® (cefiderocol) is used as empiric or documented therapy as compared to salvage therapy for the treatment of Gram-negative bacterial infections

Exclusive Licensing Agreement with Link Healthcare, a Clinigen Company for Cefiderocol in Australia and New Zealand

SHIONOGI Group Code of Conduct has been issued

Shionogi Initiates New Drug Application Submission for Ensitrelvir for Post-Exposure Prophylaxis with the U.S. Food and Drug Administration

Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Post-Exposure Prophylaxis of COVID-19.

Shionogi Announces Appointment of Corporate officers, the Establishment of new Organization and Personnel Reassignment (Effective April 1, Jun 18, and July 1, 2025)

Notice of Transition to Company with Audit and Supervisory Committee and the Candidates for Directors After the Transition

Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis

Shionogi Collaborates with RNID to Improve Communication in Healthcare Settings for Patients Who Are Deaf, Have Hearing Loss or Tinnitus

Conclusion of a Comprehensive Collaboration Agreement with Osaka Metropolitan University in the Field of Infectious Diseases ~ Aiming to Establish the 'Osaka Model' for a City Resilient to Infectious Diseases through Industry-Government-Academia Collaboration ~

Shionogi Announces Corporate Reorganization, New Establishment and Personnel Reassignment (Effective April 1, 2025)

Approval for "Fetroja®"(cefiderocol) in South Korea

Shionogi Obtains Domestic Manufacturing and Marketing Approval for the Digital Therapeutic App "ENDEAVORRIDE®" for Pediatric Attention-Deficit/Hyperactivity Disorder (ADHD)

Transcript of the FY2024 3Q Financial Results Conference

Presentation Materials for FY2024 3Q financial results

Financial Results and supplement for FY2024 3Q

Shionogi Announces Positive Results from Phase 2 Trial of Respiratory Syncytial Virus Oral Antiviral Candidate S-337395

Acceptance of a New Drug Application for the COVID-19 Treatment, Ensitrelvir Fumaric Acid, in Taiwan and Conclusion of Government Stockpiling Contract

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations